Abstract
Drug induced liver injury (DILI) is a kind of liver dysfunction which caused by drugs, and gut microbiota could affect liver injury. However, the relationship between gut microbiota and its metabolites in DILI patients is not clear. The total gut microbiota DNA was extracted from 28 DILI patient and 28 healthy control volunteers (HC) and 16S rDNA gene were amplified. Next, differentially metabolites were screened. Finally, the correlations between the diagnostic strains and differentially metabolites were studied.The richness and uniformity of the bacterial communities decreased in DILI patients, and the structure of gut microbiota changed obviously. Enterococcus and Veillonella which belong to Firmicutes increased in DILI, and Blautia and Ralstonia which belong to Firmicutes, Dialister which belongs to Proteobacteria increased in HC. In addition, these diagnostic OTUs of DILI were associated with the DILI damage mechanism. On the other hands, there were 66 differentially metabolites between DILI and HC samples, and these metabolites were mainly enriched in pyrimidine metabolism and steroid hormone biosynthesis pathways. Furthermore, the collinear network map of the key microbiota-metabolites were constructed and the results indicated that Cortodoxone, Prostaglandin I1, Bioyclo Prostaglandin E2 and Anacardic acid were positively correlated with Blautia and Ralstonia, and negatively correlated with Veillonella.This study analyzed the changes of DILI from the perspective of gut microbiota and metabolites. Key strains and differentially metabolites of DILI were screened and the correlations between them were studied. This study further illustrated the mechanism of DILI.
Similar content being viewed by others
Introduction
The digestive tract of a healthy adult contains about 1014 bacteria, which can weigh about 1–2 kg, accounting for about 78% of all the bacteria in the human body1. The structural changes of gut microbiota and liver disease interact each other. Current studies have found that gut micro-environment disorder is closely related to a variety of liver diseases, including viral hepatitis, alcoholic hepatitis, non-alcoholic fatty liver disease, autoimmune hepatitis, cirrhosis and etc.2,3,4,5,6,7,8
Gut microbiota plays important roles in the pathogenesis of liver diseases. The disorder of gut microbiota have harmful effects on the host through various ways9. Gut microbiota could influence drug metabolism directly or indirectly. The essential drug bio-transformation processes in gut microbiota include reduction and hydrolysis reactions, demethylation, deamination, dehydroxylation, deacylation, decarbonylation and oxidation10. Gut microbiota could affect the process of drug metabolism, human susceptibility to DILI, innate immune system and gene expression involved in drug metabolism10,11,12.
In our study, the total fecal microbiota DNA was extracted and the full-length of 16S rDNA gene of DILI patient and healthy control volunteers (HC) were amplified. Alpha-diversity, Beta-diversity and species composition diversity were analyzed to explore the changes of microbiota in DILI. Then, the function of the diagnostic strains and differentially metabolites were analyzed. Finally, the correlation analysis between microbiota and metabolites was performed to further understand the mechanism of key strains in DILI.
Materials and methods
Data extraction
Fecal samples were provided by 28 DILI patients and 28 healthy control volunteers (HC) from The Second affiliated Hospital of Xi'an Jiaotong University for the last two years. In department of gastroenterology, we selected inpatients who met diagnostic criteria of DILI and excluded inpatients who used antibiotics or microecological preparations in the last 3 months or had other severe diseases, like liver cancer or other gastrointestinal disorders. The total fecal microbiota DNA was extracted and full length sequence of 16S rDNA were amplified by polymerase chain reaction (PCR). Agarose gel electrophoresis (AGE) was used to detect the amplification products. Gut microbiota composition was evaluated using PacBio sequencing. The sequences were binned into operational taxonomic units (OTUs) based on 97% identification by Usearch. All participants signed informed consent forms. This study has passed the review of The Second affiliated Hospital of Xi'an Jiaotong University Ethics Committee.
Species diversity analysis
The relative abundance curve was used to reflect species diversity and abundance of samples. Alpha-diversity indexes, including Chao1, ACE, observed species and goods Coverage were compared to analysis the species richness and uniformity13. Beta-diversity analysis was used to evaluate the species complexity among different groups. In this study, principal co-ordinates analysis (PCoA) was used to show the differences in the different groups. Then, the analysis of similarities (Anosim) was used to analyze whether the differences between two groups were significantly greater than that within the groups14.
Analysis of the species composition diversity
The differences of gut microbiota composition were further analyzed. The distribution of gut microbiota at the phylum and genus level in different groups were compared, and the characteristic strains were researched by Linear discriminant analysis Effect Size (LEfSE), OTUs with relative abundance greater than 0.5% were screened for analysis based on Linear Discriminant Analysis (LDA) score (http://huttenhower.sph.harvard.edu/lefse/)15.
Functional prediction for the diagnostic OTUs
The receiver operating characteristic (ROC) curves were calculated by “pROC” R package (version 1.18.0), and the area under the ROC curve (AUC) value was used to access the distinguish ability of characteristic strains16. The functional prediction of the diagnostic strains (AUC > 0.6) were analyzed and the differences between DILI patients and HC were studied by “PICRUSt2” R package (version 0.2.3)17.
Differentially analysis of the metabolites
The metabolic differences between DILI patient and HC were showed by constructing the partial least-squares-discriminant analysis (PLS-DA) model, and the model was assessed by permutation test. Then, the metabolites were selected using three methods, including multiple change method (FC value), T test method (P value, FDR value), and PLS-DA method (VIP value). Differentially metabolites between this two groups were screened with the conditions of VIP > 1, FC ≥ 2, and p < 0.01. The “ggplot2” R package (version 3.3.3) and the “pheatmap” R package (version 1.0.12) were used to draw the volcano map and heat map, respectively18, 19. In addition, the enrichment analysis of differentially metabolites were analyzed by online website “MetaboAnalyst” (https://www.metaboanalyst.ca)20.
Correlation analysis of the microbiota and the metabolites
The correlations between the diagnostic strains and differentially metabolites were studied by “Spearman” (|r| ≥ 0.3, p < 0.05). Metabolites in the pair were regarded as key metabolites and diagnostic strains were regarded as key microbiota. Besides, the ROC curves for the key metabolites were used to access the distinguish ability. Finally, the collinear network map of the key microbiota-metabolites were constructed by “Cytoscape” (version 3.7.1)21.
Ethics approval and consent to participate
This study was performed in accordance with the Declaration of Helsinki and was approved by the medical ethics committee of the Second Affiliated Hospital of Xi'an Jiaotong University (2015162). All participants provided their written informed consent to participate in this study.
Results
Species diversity analysis
In this experiment, the relative abundance curve was balanced as the number of reads increases, which indicated that enough sequencing data were obtained and the sequencing depth were reasonable (Fig. 1A).
Alpha-diversity indexes of each group were shown in Fig. 1B. The Chao1 and ACE index of DILI groups were significantly lower than HC groups, which indicated that the richness of bacterial community decreased obviously in DILI patients (p < 0.05). On the other hands, the observed species index of DILI groups was significantly lower than HC groups, and the goods Coverage index of DILI groups was significantly higher than HC groups, which indicated that the uniformity of the bacterial communities decreased obviously in DILI patients.
The PCoA results showed that DILI patient and HC clustered separately (Fig. 1C). Besides, greater differences between groups than within-group (ANOSIM statistics = 0.0868, p = 0.01) indicated that grouping was meaningful and the structure and composition of gut microbiota were significantly changed by DILI.
Analysis of the species composition diversity
The distribution of gut microbiota at the phylum and genus level in different groups were further analyzed. At the phylum, the gut microbiota were mainly composed of Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria (Fig. 2A). Compared with the HC groups, the abundance of Bacteroidota, Firmicutes, Fusobacteriota and Acidobacteriota in DILI groups were significantly increased, and the abundance of Proteobacteria, Verrucomicrobiota and Desulfobacterota were significantly decreased (Fig. 2B). At the genus, the gut microbiota were mainly composed of Bifidobacterium, Escherichia-Shigella, Streptococcus, Faecalibacterium, Bacteroides, Blautia, Ralstonia, Klebsiella, Subdoligranulum and Dialister (Fig. 2C). The abundance of Streptococcus, Faecalibacterium, Bacteroides and Klebsiella were significantly increased, while the abundance of Bifidobacterium, Blautia, Subdoligranulum and Dialister were significantly decreased in DILI groups (Fig. 2D). To research the key gut strains, the LEfSE analysis was further conducted and differential abundance of 19 gut strains were obtained. As showed in Fig. 2E and F, Enterococcus and Veillonella which belong to Firmicutes significantly increased in DILI. Blautia and Ralstonia which belong to Firmicutes, Dialister which belongs to Proteobacteria significantly increased in HC.
Screening for the diagnostic OTUs of DILI, which associated with the DILI damage mechanism
In this study, the ROC curves of 19 characteristic strains involved were calculated and the AUC value were obtained between 0.65 and 0.9, where five out of characteristic gut microbiota at the genus level were displayed in Fig. 3A (AUCEnterococcus = 0.778, AUCVeillohella = 0.679, AUCBlautia = 0.815, AUCRalstonia = 0.853, AUCDialister = 0.657). The rest of which was shown in Supplementary Fig. S1. In addition, the functional prediction of the 19 diagnostic strains were analyzed and the results showed that 219 pathways were significantly different between the two groups, among them, 4-deoxy-L-threo-hex-4-enopyranuronate degradation pathway and superpathway of L-methionine biosynthesis (transsulfuration) were significantly highly expressed in HC groups (p < 0.05), mevalonate pathway I were significantly highly expressed in DILI groups (p < 0.05) (Fig. 3B).
The function of 66 differentially metabolites were mainly enriched in pyrimidine metabolism and steroid hormone biosynthesis pathways
The PLS-DA model was constructed and the results showed that the composition of metabolites were different between these two groups (Q2 = 0.577, R2Y = 0.906) (Fig. 4A). Totals of 66 differentially metabolites, including 56 down-regulated and 10 up-regulated metabolites were screened in DILI groups under the VIP > 1, FC ≥ 2, p < 0.01 (Fig. 4B and C). In addition, these differentially metabolites were mainly enriched in pyrimidine metabolism and steroid hormone biosynthesis pathways (Fig. 4D).
Correlation analysis of the gut microbiota and the metabolites
The correlation between the differentially metabolites and five diagnostic strains at the genus level were showed in Fig. 5A. Blautia, Dialister and Ralstonia showed a strong correlation with the Estriol, and Cortolne, respectively, Enterococcus and Veillonella showed a strong correlation with the VNH and Oleoyl dopamine, respectively. The ROC curves for key metabolites suggested that most of key metabolites have diagnostic value, with the AUC value between 0.7 and 0.95 (Supplementary Fig. S2). Furthermore, the collinear network map of the key microbiota-metabolites was constructed and the results indicated that Cortodoxone, Prostaglandin I1, Bioyclo Prostaglandin E2 and Anacardic acid were positively correlated with Blautia and Ralstonia, and negatively correlated with Veillonella (Fig. 5B).
Discussion
The human intestinal tract, especially the colon, is inhabited with a large number of microorganisms, they play central roles in the regulation of intestinal function, immune system maturation, pathogen defense, and substance metabolism22. Besides, gut microbiota are also associated with hepatic diseases. Current studies have found that gut microbiota disorder was closely related to liver diseases, including viral hepatitis, alcoholic hepatitis, non-alcoholic fatty liver disease, autoimmune hepatitis, cirrhosis and etc.2,3,4,5,6,7,8 Gut microorganisms metabolites and gut micribiota could act together on the liver, which could promote the occurrence and development of liver disease23. In vivo experiments indicated that gut microbiota and its metabolites were altered by DILI, and might involve in the process of liver injury24,25,26,27. However, the relationship among DILI, gut microbiota and metabolites are unclear, and the joint analysis between microbiome and metabolome have not been reported.
In our study, the richness and uniformity decreased obviously in DILI samples, and the species composition were different between 2 group samples. Significant changes in composition and structure of gut microbiota were confirmed in a variety of liver diseases. Zeng et al. have found that the alpha-diversity indexes of gut microbiota in patients with hepatitis B were higher than that in healthy human, and beta-diversity analysis showed significant differences between the two groups28. It has also been found that the alpha- and beta- diversity of gut microbiota were significantly altered in liver injury mouse caused by exposure to perfluorooctanoic acid (PFOA)26. Besides, a decrease in the diversity of gut microbiota has been found in mice with Acetaminophen (APAP) -induced liver injury29. Our findings are consistent with these results.
The gut bacterial strains associated with DILI identified by LEfSE analysis may be pathogenic agents of DILI and participate in the occurrence or development of DILI. These key strains may be potential biomarkers for the diagnosis or prediction of DILI on their own, or working in concert with other strains. In addition, certain strains may participate in the development of DILI as cofactors. Therefore, LEfSE analysis could help us learn more about the function and mechanisms of the strains about DILI. At the genus level, Enterococcus, Veillonella were significantly increased and Blautia, Ralstonia, Dialister were significantly decreased by DILI. Our results were similar to previous analyses. Enterococcus and Veillonella were significantly increased in Chronic viral hepatitis B3, 28. In autoimmune hepatitis, the abundance of Veillonella significantly increased, which is highly associated with primary biliary cirrhosis and primary sclerosing cholangitis30. Some studies found that the abundance of Blautia was further reduced in cirrhotic patients with hepatocellular carcinoma or HBV31. Blautia also decreased in HBV infected mice model, which may be related to the progression of liver injury31, 32. Few studies have shown the relationship between Ralstonia and liver injury. The abundance of Dialister, a beneficial bacterium, is significantly decreased in patients with chronic hepatitis B, and its decline is associated with the progression of liver injury in hepatitis B3. Enterococcus and Veillonella may be new targets for clinical diagnosis of drug-induced liver injury. In addition, in cirrhotic patients with no hepatocellular carcinoma, the abundance of Blautia and Bifidobacterium were increased, while Enterococcaceae and Enterococcus were decreased, which were different to our results31. These data showed that the gut bacterial strains were regulated by different liver injury types and disease status. Moreover, the relationship between key strains and DILI needs to be verified by further experiments in vivo and in vitro.
The functional prediction of the 19 diagnostic strains mentioned above showed that 4-deoxy-L-threo-hex-4-enopyranuronate degradation pathway and superpathway of L-methionine biosynthesis (transsulfuration) were significantly lowly expressed in DILI groups, and mevalonate pathway I were significantly highly expressed in DILI groups. The 4-deoxy-L-threo-hex-4-enopyranuronate degradation pathway, a kind of sugar derivative degradation, is involved in short chain fatty acids (SCFAs) production. Dietary soluble fibers are fermented by gut bacteria into SCFAs33. SCFAs are well known to exert a wide beneficial impact to the host34, 35. Glucuronate degradation is associated with hepatic drug metabolism36. SCFAs have been reported to be associated with liver metabolic diseases, including butyrate and valerate37, 38. Therefore, promoting the 4-deoxy-L-threo-hex-4-enopyranuronate degra dation pathway might be the key to the treatment of DILI. Mevalonate is associated with the mechanism of DILI39, 40. Previous studies showed that methionine and its metabolic enzyme levels were reduced in NAFLD, and the decreaced methionine plasma level and impairment of transsulfuration pathway in NAFLD might be related to the liver injury41, 42. S-adenosylmethionine is an effective chemopreventive agent in HCC and other cancers43. The decrease of superpathway of L-methionine biosynthesis might be associated with the liver injury. Furthermore, related studies have shown that isoprenoids, cholesterol (vital products of the mevalonate pathway) and HMG-COA (key enzymes of mevalonate pathway) were significantly associated with liver injury44, 45. Besides, Liu et al. showed that the importance of cholesterol/mevalonate pathway in the progress of NAFLD46. Therefore, the mevalonate pathway I may affect the process of DILI by producing isoprenoids and cholesterol et al. Bile acid (BA) metabolism is associated with the development of liver injury. The treatment of NAFLD by interfering with BA synthesis and metabolism has become a new research direction. But we didn’t find BA metabolism enriched pathway in our results47. These data showed that the BA metabolism was not the main process in development of DILI. Furthermore, the effect of gut metabolic products on DILI needs more studies to verify.
Previous study showed that pyrimidine metabolism is linked to liver injury, such as fatty liver and alcoholic liver disease48, 49. Sexual hormones and adrenocortical hormone are products of steroidhormone biosynthesis. Sexual hormones affect endogenous and exogenous metabolism in the liver and involve in the pathogenesis of functional and structural disorders of the liver, including the development of hepatic steatosis, fibrosis, and carcinogenesis50. Elevated levels of glucocorticoids play an important role in the pathogenesis of nonalcoholic fatty liver disease, which might caused by hepatic cholesterol synthesis increasing and utilization decreasing51. Numerous studies have demonstrated that cirrhosis and noncritical chronic liver disease are associated with relative adrenal insufficiency (RAI)52,53,54. RAI is the term given to inadequate production of cortisol relative to the severity of illness52.The pyrimidine metabolism and steroid hormone biosynthesis pathways of differentially metabolites maybe involved in the progress of DILI. Prostaglandins (PG), belonged to eicosanoids, formed via the cyclooxygenase pathway55. Eicosanoids implicate the regulation of hepatocyte proliferation, liver regeneration and liver injury and recovery55. PG in protecting liver to the hepatic ischemia and reperfusion damage has been extensively studied56. Prostaglandin E2 (PGE2) could retard CCl4-induced liver fibrosis in rats55, 57, 58. Anacardic acid could trigger the classic activation pathway in macrophages by phosphorylating mitogen-activated protein kinases, thereby activating innate immunity59, 60. Besides, anacardic acid has been confirmed to have antitumor effects in some preclinical models61. In our study, Cortodoxone, Prostaglandin I1, Bioyclo PGE2 and Anacardic acid were also positively correlated with Blautia and Ralstonia, and negatively correlated with Veillonella. This shows that our results are reliable.
There are some potential limitations with this study. The study’s sample size was not large enough, even though the results were statistically significant. The conclusion of the study does not connect to clinical information. The results of this study showed the correlation among DILI, gut bacterial strains and metabolic products, but the results didn’t tell the causal relationship among them. We will collect more samples of DILI patients for further research through effective measures such as setting up a registration database and establishing communication with patients. In addition, the effect of clinical information such as age, sex, medical history, and disease status on key strains and differential metabolic products need further studies. We will perform experiments in vivo and in vitro to verify the function of gut bacterial strains and metabolic products in DILI, and figure out the causal relationship among them to promote our knowledge and understanding of DILI.
In conclusion, this study analyzed the changes of DILI from the perspective of gut microbiota and metabolites. The richness and uniformity of the bacterial communities decreased in DILI patients, and the structure of gut microbiota changed obviously. Key strains and differentially metabolites of DILI were screened and the correlations between the them were studied. Enterococcus and Veillonella which belong to Firmicutes increased, Blautia and Ralstonia which belong to Firmicutes, Dialister which belongs to Proteobacteria decreased in DILI. Differentially metabolites between DILI and HC samples were mainly enriched in pyrimidine metabolism and steroid hormone biosynthesis pathways. Furthermore, the Cortodoxone, Prostaglandin I1, Bioyclo Prostaglandin E2 and Anacardic acid were positively correlated with Blautia and Ralstonia, and negatively correlated with Veillonella. This study further illustrated the role of gut microbiota and metabolites in progress of DILI. We will continue focus on the mechanism of gut microbiota and its metabolites in DILI.
Data availability
All data and material are available upon request to correspondence author.
References
Khanna, S. & Tosh, P. K. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clin. Proc. 89(1), 107–114 (2014).
Xu, D., Huang, Y. & Wang, J. Gut microbiota modulate the immune effect against hepatitis B virus infection. Eur. J. Clin. Microbiol. Infect. Dis. 34(11), 2139–2147 (2015).
Chen, Z. et al. Featured gut microbiomes associated with the progression of chronic hepatitis B disease. Front. Microbiol. 11, 383 (2020).
Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16(4), 235–246 (2019).
Safari, Z. & Gerard, P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol. Life Sci. 76(8), 1541–1558 (2019).
Elsherbiny, N. M. et al. Autoimmune hepatitis: Shifts in gut microbiota and metabolic pathways among Egyptian patients. Microorganisms 8(7), 1011 (2020).
Ren, Z. et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 68(6), 1014–1023 (2019).
Inoue, T. et al. Gut dysbiosis associated with hepatitis C virus infection. Clin. Infect. Dis. 67(6), 869–877 (2018).
Hartmann, P. et al. Gut microbiota in liver disease: Too much is harmful, nothing at all is not helpful either. Am. J. Physiol. Gastrointest. Liver Physiol. 316(5), G563–G573 (2019).
Wilson, I. D. & Nicholson, J. K. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl. Res. 179, 204–222 (2017).
Yip, L. Y. et al. The liver-gut microbiota axis modulates hepatotoxicity of tacrine in the rat. Hepatology 67(1), 282–295 (2018).
Toda, T. et al. Ciprofloxacin suppresses Cyp3a in mouse liver by reducing lithocholic acid-producing intestinal flora. Drug Metab. Pharmacokinet. 24(3), 201–208 (2009).
Mohakud, S. et al. Isolated sacral vertebral hydatid cyst presenting with pathological fracture. J. Neurosci. Rural Pract. 10(3), 565–566 (2019).
Yu, D. et al. The gut microbiome and metabolites are altered and interrelated in patients with rheumatoid arthritis. Front. Cell Infect. Microbiol. 11, 763507 (2021).
Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12(6), R60 (2011).
Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf. 12, 77 (2011).
Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38(6), 685–688 (2020).
Liu, S. et al. Identification of key circRNAs/lncRNAs/miRNAs/mRNAs and pathways in preeclampsia using bioinformatics analysis. Med. Sci. Monit. 25, 1679–1693 (2019).
Diao, C., Xi, Y. & Xiao, T. Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol. Lett. 15(3), 2789–2794 (2018).
Chong, J., Wishart, D. S. & Xia, J. Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis. Curr Protoc Bioinformatics 68(1), e86 (2019).
Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13(11), 2498–2504 (2003).
Konturek, P. C. et al. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extra-gastrointestinal diseases. J. Physiol. Pharmacol. 66(4), 483–491 (2015).
Wiest, R. et al. Targeting the gut-liver axis in liver disease. J. Hepatol. 67(5), 1084–1103 (2017).
Neag, M. A. et al. Probiotic bacillus spores protect against acetaminophen induced acute liver injury in Rats. Nutrients 12(3), 632 (2020).
Chen, X. et al. Hepatoprotective effects of lactobacillus on carbon tetrachloride-induced acute liver injury in mice. Int. J. Mol. Sci. 19(8), 2212 (2018).
Wang, G. et al. Perfluorooctanoic acid-induced liver injury is potentially associated with gut microbiota dysbiosis. Chemosphere 266, 129004 (2021).
Wu, G. et al. Gut microbiota and liver injury (I)-acute liver injury. Adv. Exp. Med. Biol. 1238, 23–37 (2020).
Zeng, Y. et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. J. Viral. Hepat. 27(2), 143–155 (2020).
Schneider, K. M. et al. Intestinal dysbiosis amplifies acetaminophen-induced acute liver injury. Cell Mol. Gastroenterol. Hepatol. 11(4), 909–933 (2021).
Wei, Y. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut 69(3), 569–577 (2020).
Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69(1), 107–120 (2019).
Li, X. et al. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. Int. J. Antimicrob. Agents 56(1), 106000 (2020).
Singh, V. et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175(3), 679–694 (2018).
Martin-Gallausiaux, C. et al. SCFA: Mechanisms and functional importance in the gut. Proc. Nutr. Soc. 80(1), 37–49 (2021).
Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51(4), 600–605 (2019).
Linster, C. L. & Van Schaftingen, E. Glucuronate, the precursor of vitamin C, is directly formed from UDP-glucuronate in liver. FEBS J. 273(7), 1516–1527 (2006).
Ji, Y. et al. Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients 11(8), 1712 (2019).
Rau, M. et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United Eur. Gastroenterol. J. 6(10), 1496–1507 (2018).
Marinier, E. et al. Contribution of the shunt pathway of mevalonate metabolism to the regulation of cholesterol synthesis in rat liver. J. Biol. Chem. 262(35), 16936–16940 (1987).
Kromer, A. & Moosmann, B. Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways. Mol. Pharmacol. 75(6), 1421–1429 (2009).
Lee, T. D. et al. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin. Exp. Res. 28(1), 173–181 (2004).
Horowitz, J. H. et al. Evidence for impairment of transsulfuration pathway in cirrhosis. Gastroenterology 81(4), 668–675 (1981).
Mato, J. M. & Lu, S. C. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45(5), 1306–1312 (2007).
Goldstein, J. L. & Brown, M. S. Regulation of the mevalonate pathway. Nature 343(6257), 425–430 (1990).
Li, X. et al. NMR-based metabonomic and quantitative real-time PCR in the profiling of metabolic changes in carbon tetrachloride-induced rat liver injury. J. Pharm. Biomed. Anal. 89, 42–49 (2014).
Liu, J. et al. Geranylgeranyl diphosphate synthase (GGPPS) regulates non-alcoholic fatty liver disease (NAFLD)-fibrosis progression by determining hepatic glucose/fatty acid preference under high-fat diet conditions. J. Pathol. 246(3), 277–288 (2018).
Bing, H. & Li, Y. L. The role of bile acid metabolism in the occurrence and development of NAFLD. Front. Mol. Biosci. 9, 1089359 (2022).
Le, T. T. et al. Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J. Lipid. Res. 54(4), 1044–1057 (2013).
Ma, T. et al. Differential metabolic pathways and metabolites in a C57BL/6J mouse model of alcoholic liver disease. Med. Sci. Monit. 26, e924602 (2020).
Grossmann, M. et al. Reproductive endocrinology of nonalcoholic fatty liver disease. Endocr. Rev. 40(2), 417–446 (2019).
Malespin, M. & Nassri, A. Endocrine diseases and the liver: An update. Clin. Liver Dis. 23(2), 233–246 (2019).
Trifan, A., Chiriac, S. & Stanciu, C. Update on adrenal insufficiency in patients with liver cirrhosis. World J. Gastroenterol. 19(4), 445–456 (2013).
Singh, R. R. et al. Relative adrenal insufficiency in cirrhotic patients with ascites (hepatoadrenal syndrome). Dig. Liver Dis. 50(11), 1232–1237 (2018).
Park, S. H. et al. Clinical characteristics and prevalence of adrenal insufficiency in hemodynamically stable patients with cirrhosis. Med. (Baltim.) 97(26), e11046 (2018).
Alvarez, M. L. & Lorenzetti, F. Role of eicosanoids in liver repair, regeneration and cancer. Biochem. Pharmacol. 192, 114732 (2021).
Barone, S. et al. Distinct and sequential upregulation of genes regulating cell growth and cell cycle progression during hepatic ischemia-reperfusion injury. Am. J. Physiol. Cell Physiol. 289(4), C826–C835 (2005).
Zakaria, S. & El-Sisi, A. Rebamipide retards CCl4-induced hepatic fibrosis in rats: Possible role for PGE2. J. Immunotoxicol. 13(4), 453–462 (2016).
Motino, O. et al. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Biochim. Biophys. Acta 1862(9), 1710–1723 (2016).
Lu, Y. et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J. Hematol. Oncol. 15(1), 47 (2022).
Gnanaprakasam, J. N. R., Estrada-Muniz, E. & Vega, L. The anacardic 6-pentadecyl salicylic acid induces macrophage activation via the phosphorylation of ERK1/2, JNK, P38 kinases and NF-kappaB. Int. Immunopharmacol. 29(2), 808–817 (2015).
Hemshekhar, M. et al. Emerging roles of anacardic acid and its derivatives: a pharmacological overview. Basic Clin. Pharmacol. Toxicol. 110(2), 122–132 (2012).
Funding
This work was supported by the grant from Shaanxi Provincial science and technology overall planning and innovation project. [No. 2016KTCL03-04].
Author information
Authors and Affiliations
Contributions
K.H. performed the data collection, data analysis and wrote the manuscript; M.L. performed the data collection and analysis; Q.W. performed the data collection and analysis; S.C. performed the data collection; X.G. performed the conceptualization, supervision and editing. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
He, K., Liu, M., Wang, Q. et al. Combined analysis of 16S rDNA sequencing and metabolomics to find biomarkers of drug-induced liver injury. Sci Rep 13, 15138 (2023). https://doi.org/10.1038/s41598-023-42312-w
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-023-42312-w
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.